Musculoskeletal Disorders Drugs Global Market Report 2022 – By Type (Drugs For Rheumatoid Arthritis, Muscle Relaxants, Other Musculoskeletal Disorders Drugs), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies/ Drug Stores, Others), By Route Of Administration (Oral, Parenteral, Others), By Drug Classification (Branded Drugs, Generic Drugs), By Mode Of Purchase (Prescription-Based Drugs, Over-The-Counter Drugs) – Market Size, Trends, And Global Forecast 2022-2026

Musculoskeletal Disorders Drugs Global Market Report 2022

Starting Price : $5000.00 $4000.00 | Pages : 300 | Published : March 2024 | Delivery Time: 2-3 business days | Format : pdf

Need assistance or more information before the purchase?

Enquire Before Buying

Proud Members Of

checkslacipN checkaoirsN checkscipN

The musculoskeletal disorders drugs market consists of sales of musculoskeletal disorders drugs and related services by entities (organizations, sole traders and partnerships) that produce musculoskeletal disorders drugs to treat musculoskeletal disorders such as arthritis, osteoporosis, osteomalacia, and other disorders. This industry includes establishments that produce drugs to treat rheumatoid arthritis, muscle relaxants to reduce muscle pain, and other drugs used in treating osteoarthritis, analgesics drugs, immunosuppressive. Some of the major drugs in the market include Piroxicam Glaxo, Dolonex, Felden, and Piroxicam Pfizer.

The main types of musculoskeletal disorders drugs are drugs for rheumatoid arthritis, muscle relaxants and other musculoskeletal disorders drugs. A muscle relaxant is a medication that causes muscle contractions to cease. The drugs are administered through oral, parenteral, and others that are classified into branded and generic drugs. The various mode of purchase includes prescription-based drugs and over-the-counter drugs which are distributed by hospital pharmacies, retail pharmacies/ drug stores and others.

The global musculoskeletal disorders drugs market size is expected to grow from $897.45 billion in 2021 to $104.03 billion in 2022 at a compound annual growth rate (CAGR) of 6.8%. The growth in the market is mainly due to the companies rearranging their operations and recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The musculoskeletal disorders drugs market is expected to reach $163.94 billion in 2026 at a CAGR of 12%.

The aging population profile of most countries contributed to the growth of the musculoskeletal disorders drugs market. The increase in patient pool due to rising geriatric population globally, contributed significantly to the growth of the market during the historic period. According to the WHO, by 2030, one in every six people on the planet will be 60 or older. The proportion of the population aged 60 and up will rise from 1 billion in 2020 to 2.1 billion by 2050. This rise in the geriatric population increased the demand for medical care and drove the healthcare expenditure. This has led to increased demand for pharmaceuticals products, significantly impacting market growth during this period.

Regulatory changes are likely to lead to increased costs relating to new product development and service offerings to clients. These changes are related to data protection such as the European Union's General Data Protection Regulation (GDPR), changes to drug approval procedures and other regulatory changes. For instance, according to a study on 100 Data Privacy and Data Security statistics for 2020, GDPR compliance is a top priority for 58% of European companies. The GDPR regulation is a EU law on data protection and privacy of individuals residing the European Union and the European Economic Area (EEA). It also regulates data anonymization thus maintaining integrity of data dealing with patients and other clinical trial studies. The potential loss of revenue due to delays in product release and additional costs incurred due to stringent approval processes puts strain to investments relating to new product development, thereby affecting the growth of the musculoskeletal disorders drugs market.

Going forward, the market for muscle relaxants is expected to increase with the rise in combination therapy. Combination therapy involves use of more than one medication or drug to treat a disease. These combinational therapies reduce the frequency of drug administration. For instance, in May 2019, Galt Pharmaceuticals has submitted a Supplemental Abbreviated New Drug Application to the U.S. Food and Drug Administration for Orphengesic Forte an oral formulation of aspirin, caffeine, and orphenadrine for the treatment of pain caused due to musculoskeletal disorders.

Major companies in the musculoskeletal disorders drugs market include Sanofi S.A, Pfizer Inc., Bristol-Myers Squibb, Eli Lilly And Company, Mitsubishi Tanabe Pharma Corporation, Horizon Therapeutics plc, Procter & Gamble, Eisai Co. Ltd, Biogen Inc and Sino Biopharmaceutical.

North America was the largest region in the musculoskeletal disorders drugs market in 2021. The Middle East is expected to be the fastest growing region in the forecast period. The regions covered in the musculoskeletal disorders drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the musculoskeletal disorders drugs market report are Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, China, Colombia, Czech Republic, Denmark, Egypt, Finland, France, Germany, Hong Kong, India, Indonesia, Ireland, Israel, Italy, Japan, Malaysia, Mexico, Netherlands, New Zealand, Nigeria, Norway, Peru, Philippines, Poland, Portugal, Romania, Russia, Saudi Arabia, Singapore, South Africa, South Korea, Spain, Sweden, Switzerland, Thailand, Turkey, UAE, UK, USA, Venezuela and Vietnam.

The global musculoskeletal disorders drugs market is segmented -

1) By Type: Drugs for Rheumatoid Arthritis, Muscle Relaxants, Other Musculoskeletal Disorders Drugs

2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies/ Drug Stores, Others

3) By Route of Administration: Oral, Parenteral, Others

4) By Drug Classification: Branded Drugs, Generic Drugs

5) By Mode of Purchase: Prescription-Based Drugs, Over-The-Counter Drugs

    Table Of Contents

    1. Executive Summary

    2. Report Structure

    3. Musculoskeletal Disorders Drugs Market Characteristics

    3.1. Market Definition

    3.2. Key Segmentations

    4. Musculoskeletal Disorders Drugs Market Product Analysis

    4.1. Leading Products/ Services

    4.2. Key Features and Differentiators

    4.3. Development Products

    5. Musculoskeletal Disorders Drugs Market Supply Chain

    5.1. Supply Chain

    5.2. Distribution

    5.3. End Customers

    6. Musculoskeletal Disorders Drugs Market Customer Information

    6.1. Customer Preferences

    6.2. End Use Market Size and Growth

    7. Musculoskeletal Disorders Drugs Market Trends And Strategies

    8. Impact Of COVID-19 On Musculoskeletal Disorders Drugs

    9. Musculoskeletal Disorders Drugs Market Size And Growth

    9.1. Market Size

    9.2. Historic Market Growth, Value ($ Billion)

    9.2.1. Drivers Of The Market

    9.2.2. Restraints On The Market

    9.3. Forecast Market Growth, Value ($ Billion)

    9.3.1. Drivers Of The Market

    9.3.2. Restraints On The Market

    10. Musculoskeletal Disorders Drugs Market Regional Analysis

    10.1. Global Musculoskeletal Disorders Drugs Market, 2021, By Region, Value ($ Billion)

    10.2. Global Musculoskeletal Disorders Drugs Market, 2016-2021, 2021-2026F, 2031F, Historic And Forecast, By Region

    10.3. Global Musculoskeletal Disorders Drugs Market, Growth And Market Share Comparison, By Region

    11. Musculoskeletal Disorders Drugs Market Segmentation

    11.1. Global Musculoskeletal Disorders Drugs Market, Segmentation By Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    Drugs For Rheumatoid Arthritis

    Muscle Relaxants

    Other Musculoskeletal Disorders Drugs

    11.2. Global Musculoskeletal Disorders Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    Hospital Pharmacies

    Retail Pharmacies/ Drug Stores

    Others

    11.3. Global Musculoskeletal Disorders Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    Oral

    Parenteral

    Others

    11.4. Global Musculoskeletal Disorders Drugs Market, Segmentation By Drug Classification, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    Branded Drugs

    Generic Drugs

    11.5. Global Musculoskeletal Disorders Drugs Market, Segmentation By Mode Of Purchase, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    Prescription-Based Drugs

    Over-The-Counter Drugs

    12. Musculoskeletal Disorders Drugs Market Metrics

    12.1. Musculoskeletal Disorders Drugs Market Size, Percentage Of GDP, 2016-2026, Global

    12.2. Per Capita Average Musculoskeletal Disorders Drugs Market Expenditure, 2016-2026, Global

    13. Asia-Pacific Musculoskeletal Disorders Drugs Market

    13.1. Asia-Pacific Musculoskeletal Disorders Drugs Market Overview

    Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

    13.2. Asia-Pacific, Musculoskeletal Disorders Drugs Market, 2021, By Country, Value ($ Billion)

    13.3. Asia-Pacific, Musculoskeletal Disorders Drugs Market, 2016-2021, 2021-2026F, 2031F, Historic And Forecast, By Country

    13.4. Asia-Pacific, Musculoskeletal Disorders Drugs Market, 2016-2021, 2021-2026F, 2031F, Growth And Market Share Comparison, By Country

    13.5. Asia-Pacific, Musculoskeletal Disorders Drugs Market Metrics

    13.5.1. Per Capita Average Musculoskeletal Disorders Drugs Expenditure, 2016-2026, Asia-Pacific Countries

    13.5.2. Rheumatoid Arthritis Prevalence Rate, Musculoskeletal Disorders Drugs Market, Musculoskeletal Disorders Drugs Market/Rheumatoid Arthritis Prevalence Rate, 2021, Asia-Pacific Countries

    13.6. Asia-Pacific Musculoskeletal Disorders Drugs Market, Segmentation By Type, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)

    13.7. Asia-Pacific Musculoskeletal Disorders Drugs Market: Country Analysis

    13.7.1. China Musculoskeletal Disorders Drugs Market

    13.7.1.1. China Musculoskeletal Disorders Drugs Market Overview

    13.7.1.2. China Musculoskeletal Disorders Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)

    13.7.1.3. China Musculoskeletal Disorders Drugs Market, Segmentation By Type, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)

    13.7.2. Australia Musculoskeletal Disorders Drugs Market

    13.7.2.1. Australia Musculoskeletal Disorders Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)

    13.7.2.2. Australia Musculoskeletal Disorders Drugs Market, Segmentation By Type, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)

    13.7.3. Hong Kong Musculoskeletal Disorders Drugs Market

    13.7.3.1. Hong Kong Musculoskeletal Disorders Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)

    13.7.4. India Musculoskeletal Disorders Drugs Market

    13.7.4.1. India Musculoskeletal Disorders Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)

    13.7.4.2. India Musculoskeletal Disorders Drugs Market, Segmentation By Type, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)

    13.7.5. Indonesia Musculoskeletal Disorders Drugs Market

    13.7.5.1. Indonesia Musculoskeletal Disorders Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)

    13.7.5.2. Indonesia Musculoskeletal Disorders Drugs Market, Segmentation By Type, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)

    13.7.6. Japan Musculoskeletal Disorders Drugs Market

    13.7.6.1. Japan Musculoskeletal Disorders Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)

    13.7.6.2. Japan Musculoskeletal Disorders Drugs Market, Segmentation By Type, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)

    13.7.7. Malaysia Musculoskeletal Disorders Drugs Market

    13.7.7.1. Malaysia Musculoskeletal Disorders Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)

    13.7.8. New Zealand Musculoskeletal Disorders Drugs Market

    13.7.8.1. New Zealand Musculoskeletal Disorders Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)

    13.7.9. Philippines Musculoskeletal Disorders Drugs Market

    13.7.9.1. Philippines Musculoskeletal Disorders Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)

    13.7.10. Singapore Musculoskeletal Disorders Drugs Market

    13.7.10.1. Singapore Musculoskeletal Disorders Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)

    13.7.11. South Korea Musculoskeletal Disorders Drugs Market

    13.7.11.1. South Korea Musculoskeletal Disorders Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)

    13.7.11.2. South Korea Musculoskeletal Disorders Drugs Market, Segmentation By Type, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)

    13.7.12. Thailand Musculoskeletal Disorders Drugs Market

    13.7.12.1. Thailand Musculoskeletal Disorders Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)

    13.7.13. Vietnam Musculoskeletal Disorders Drugs Market

    13.7.13.1. Vietnam Musculoskeletal Disorders Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)

    14. Western Europe Musculoskeletal Disorders Drugs Market

    14.1. Western Europe Musculoskeletal Disorders Drugs Market Overview

    14.2. Western Europe, Musculoskeletal Disorders Drugs Market, 2021, By Country, Value ($ Billion)

    14.3. Western Europe, Musculoskeletal Disorders Drugs Market, 2016-2021, 2021-2026F, 2031F, Historic And Forecast, By Country

    14.4. Western Europe, Musculoskeletal Disorders Drugs Market, 2016-2021, 2021-2026F, 2031F, Growth And Market Share Comparison, By Country

    14.5. Western Europe, Musculoskeletal Disorders Drugs Market Metrics

    14.5.1. Per Capita Average Musculoskeletal Disorders Drugs Expenditure, 2016-2026, Western Europe Countries

    14.5.2. Rheumatoid Arthritis Prevalence Rate, Musculoskeletal Disorders Drugs Market, Musculoskeletal Disorders Drugs Market/Rheumatoid Arthritis Prevalence Rate, 2021, Western Europe Countries

    14.6. Western Europe Musculoskeletal Disorders Drugs Market, Segmentation By Type, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)

    14.7. Western Europe Musculoskeletal Disorders Drugs Market: Country Analysis

    14.7.1. Austria Musculoskeletal Disorders Drugs Market

    14.7.1.1. Austria Musculoskeletal Disorders Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)

    14.7.2. Belgium Musculoskeletal Disorders Drugs Market

    14.7.2.1. Belgium Musculoskeletal Disorders Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)

    14.7.3. Denmark Musculoskeletal Disorders Drugs Market

    14.7.3.1. Denmark Musculoskeletal Disorders Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)

    14.7.4. Finland Musculoskeletal Disorders Drugs Market

    14.7.4.1. Finland Musculoskeletal Disorders Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)

    14.7.5. France Musculoskeletal Disorders Drugs Market

    14.7.5.1. France Musculoskeletal Disorders Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)

    14.7.5.2. France Musculoskeletal Disorders Drugs Market, Segmentation By Type, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)

    14.7.6. Germany Musculoskeletal Disorders Drugs Market

    14.7.6.1. Germany Musculoskeletal Disorders Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)

    14.7.6.2. Germany Musculoskeletal Disorders Drugs Market, Segmentation By Type, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)

    14.7.7. Ireland Musculoskeletal Disorders Drugs Market

    14.7.7.1. Ireland Musculoskeletal Disorders Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)

    14.7.8. Italy Musculoskeletal Disorders Drugs Market

    14.7.8.1. Italy Musculoskeletal Disorders Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)

    14.7.9. Netherlands Musculoskeletal Disorders Drugs Market

    14.7.9.1. Netherlands Musculoskeletal Disorders Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)

    14.7.10. Norway Musculoskeletal Disorders Drugs Market

    14.7.10.1. Norway Musculoskeletal Disorders Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)

    14.7.11. Portugal Musculoskeletal Disorders Drugs Market

    14.7.11.1. Portugal Musculoskeletal Disorders Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)

    14.7.12. Spain Musculoskeletal Disorders Drugs Market

    14.7.12.1. Spain Musculoskeletal Disorders Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)

    14.7.13. Sweden Musculoskeletal Disorders Drugs Market

    14.7.13.1. Sweden Musculoskeletal Disorders Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)

    14.7.14. Switzerland Musculoskeletal Disorders Drugs Market

    14.7.14.1. Switzerland Musculoskeletal Disorders Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)

    14.7.15. UK Musculoskeletal Disorders Drugs Market

    14.7.15.1. UK Musculoskeletal Disorders Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)

    14.7.15.2. UK Musculoskeletal Disorders Drugs Market, Segmentation By Type, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)

    15. Eastern Europe Musculoskeletal Disorders Drugs Market

    15.1. Eastern Europe Musculoskeletal Disorders Drugs Market Overview

    15.2. Eastern Europe, Musculoskeletal Disorders Drugs Market, 2021, By Country, Value ($ Billion)

    15.3. Eastern Europe, Musculoskeletal Disorders Drugs Market, 2016-2021, 2021-2026F, 2031F, Historic And Forecast, By Country

    15.4. Eastern Europe, Musculoskeletal Disorders Drugs Market, 2016-2021, 2021-2026F, 2031F, Growth And Market Share Comparison, By Country

    15.5. Eastern Europe, Musculoskeletal Disorders Drugs Market Metrics

    15.5.1. Per Capita Average Musculoskeletal Disorders Drugs Expenditure, 2016-2026, Eastern Europe Countries

    15.5.2. Rheumatoid Arthritis Prevalence Rate, Musculoskeletal Disorders Drugs Market, Musculoskeletal Disorders Drugs Market/Rheumatoid Arthritis Prevalence Rate, 2021, Eastern Europe Countries

    15.6. Eastern Europe Musculoskeletal Disorders Drugs Market, Segmentation By Type, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)

    15.7. Eastern Europe Musculoskeletal Disorders Drugs Market: Country Analysis

    15.7.1. Czech Republic Musculoskeletal Disorders Drugs Market,  

    15.7.1.1. Czech Republic Musculoskeletal Disorders Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)

    15.7.2. Poland Musculoskeletal Disorders Drugs Market

    15.7.2.1. Poland Musculoskeletal Disorders Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)

    15.7.3. Romania Musculoskeletal Disorders Drugs Market

    15.7.3.1. Romania Musculoskeletal Disorders Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)

    15.7.4. Russia Musculoskeletal Disorders Drugs Market

    15.7.4.1. Russia Musculoskeletal Disorders Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)

    15.7.4.2. Russia Musculoskeletal Disorders Drugs Market, Segmentation By Type, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)

    16. North America Musculoskeletal Disorders Drugs Market

    16.1. North America Musculoskeletal Disorders Drugs Market Overview

    16.2. North America, Musculoskeletal Disorders Drugs Market, 2021, By Country, Value ($ Billion)

    16.3. North America, Musculoskeletal Disorders Drugs Market, 2016-2021, 2021-2026F, 2031F, Historic And Forecast, By Country

    16.4. North America, Musculoskeletal Disorders Drugs Market, 2016-2021, 2021-2026F, 2031F, Growth And Market Share Comparison, By Country

    16.5. North America, Musculoskeletal Disorders Drugs Market Metrics

    16.5.1. Per Capita Average Musculoskeletal Disorders Drugs Expenditure, 2016-2026, North America Countries

    16.5.2. Rheumatoid Arthritis Prevalence Rate, Musculoskeletal Disorders Drugs Market, Musculoskeletal Disorders Drugs Market/Rheumatoid Arthritis Prevalence Rate, 2021, North America Countries

    16.6. North America Musculoskeletal Disorders Drugs Market, Segmentation By Type, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)

    16.7. North America Musculoskeletal Disorders Drugs Market: Country Analysis

    16.7.1. Canada Musculoskeletal Disorders Drugs Market

    16.7.1.1. Canada Musculoskeletal Disorders Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)

    16.7.2. Mexico Musculoskeletal Disorders Drugs Market

    16.7.2.1. Mexico Musculoskeletal Disorders Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)

    16.7.3. USA Musculoskeletal Disorders Drugs Market

    16.7.3.1. USA Musculoskeletal Disorders Drugs Market Overview

    16.7.3.2. USA Musculoskeletal Disorders Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)

    16.7.3.3. USA Musculoskeletal Disorders Drugs Market, Segmentation By Type, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)

    17. South America Musculoskeletal Disorders Drugs Market

    17.1. South America Musculoskeletal Disorders Drugs Market Overview

    17.2. South America, Musculoskeletal Disorders Drugs Market, 2021, By Country, Value ($ Billion)

    17.3. South America, Musculoskeletal Disorders Drugs Market, 2016-2021, 2021-2026F, 2031F, Historic And Forecast, By Country

    17.4. South America, Musculoskeletal Disorders Drugs Market, 2016-2021, 2021-2026F, 2031F, Growth And Market Share Comparison, By Country

    17.5. South America, Musculoskeletal Disorders Drugs Market Metrics

    17.5.1. Per Capita Average Musculoskeletal Disorders Drugs Expenditure, 2016-2026, South America Countries

    17.5.2. Rheumatoid Arthritis Prevalence Rate, Musculoskeletal Disorders Drugs Market, Musculoskeletal Disorders Drugs Market/Rheumatoid Arthritis Prevalence Rate, 2021, South America Countries

    17.6. South America Musculoskeletal Disorders Drugs Market, Segmentation By Type, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)

    17.7. South America Musculoskeletal Disorders Drugs Market: Country Analysis

    17.7.1. Argentina Musculoskeletal Disorders Drugs Market

    17.7.1.1. Argentina Musculoskeletal Disorders Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)

    17.7.2. Brazil Musculoskeletal Disorders Drugs Market

    17.7.1.1. Brazil Musculoskeletal Disorders Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)

    17.7.2.2. Brazil Musculoskeletal Disorders Drugs Market, Segmentation By Type, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)

    17.7.3. Chile Musculoskeletal Disorders Drugs Market

    17.7.3.1. Chile Musculoskeletal Disorders Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)

    17.7.4. Colombia Musculoskeletal Disorders Drugs Market

    17.7.4.1. Colombia Musculoskeletal Disorders Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)

    17.7.5. Peru Musculoskeletal Disorders Drugs Market

    17.7.5.1. Peru Musculoskeletal Disorders Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)

    17.7.6. Venezuela Musculoskeletal Disorders Drugs Market

    17.7.6.1. Venezuela Musculoskeletal Disorders Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)

    18. Middle East Musculoskeletal Disorders Drugs Market

    18.1. Middle East Musculoskeletal Disorders Drugs Market Overview

    18.2. Middle East, Musculoskeletal Disorders Drugs Market, 2021, By Country, Value ($ Billion)

    18.3. Middle East, Musculoskeletal Disorders Drugs Market, 2016-2021, 2021-2026F, 2031F, Historic And Forecast, By Country

    18.4. Middle East, Musculoskeletal Disorders Drugs Market, 2016-2021, 2021-2026F, 2031F, Growth And Market Share Comparison, By Country

    18.5. Middle East, Musculoskeletal Disorders Drugs Market Metrics

    18.5.1. Per Capita Average Musculoskeletal Disorders Drugs Expenditure, 2016-2026, Middle East Countries

    18.5.2. Rheumatoid Arthritis Prevalence Rate, Musculoskeletal Disorders Drugs Market, Musculoskeletal Disorders Drugs Market/Rheumatoid Arthritis Prevalence Rate, 2021, Middle East Countries

    18.6. Middle East Musculoskeletal Disorders Drugs Market, Segmentation By Type, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)

    18.7. Middle East Musculoskeletal Disorders Drugs Market: Country Analysis

    18.7.1. Saudi Arabia Musculoskeletal Disorders Drugs Market

    18.7.1.1. Saudi Arabia Musculoskeletal Disorders Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)

    18.7.2. Israel Musculoskeletal Disorders Drugs Market

    18.7.2.1. Israel Musculoskeletal Disorders Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)

    18.7.3. Turkey Musculoskeletal Disorders Drugs Market

    18.7.3.1. Turkey Musculoskeletal Disorders Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)

    18.7.4. UAE Musculoskeletal Disorders Drugs Market

    18.7.4.1. UAE Musculoskeletal Disorders Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)

    19. Africa Musculoskeletal Disorders Drugs Market

    19.1. Africa Musculoskeletal Disorders Drugs Market Overview

    19.2. Africa, Musculoskeletal Disorders Drugs Market, 2021, By Country, Value ($ Billion)

    19.3. Africa, Musculoskeletal Disorders Drugs Market, 2016-2021, 2021-2026F, 2031F, Historic And Forecast, By Country

    19.4. Africa, Musculoskeletal Disorders Drugs Market, 2016-2021, 2021-2026F, 2031F, Growth And Market Share Comparison, By Country

    19.5. Africa, Musculoskeletal Disorders Drugs Market Metrics

    19.5.1. Per Capita Average Musculoskeletal Disorders Drugs Expenditure, 2016-2026, Africa Countries

    19.5.2. Rheumatoid Arthritis Prevalence Rate, Musculoskeletal Disorders Drugs Market, Musculoskeletal Disorders Drugs Market/Rheumatoid Arthritis Prevalence Rate, 2021, Africa Countries

    19.6. Africa Musculoskeletal Disorders Drugs Market, Segmentation By Type, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)

    19.7. Africa Musculoskeletal Disorders Drugs Market: Country Analysis

    19.7.1. Egypt Musculoskeletal Disorders Drugs Market

    19.7.1.1. Egypt Musculoskeletal Disorders Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)

    19.7.2. Nigeria Musculoskeletal Disorders Drugs Market

    19.7.2.1. Nigeria Musculoskeletal Disorders Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)

    19.7.3. South Africa Musculoskeletal Disorders Drugs Market

    19.7.3.1. South Africa Musculoskeletal Disorders Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)

    20. Musculoskeletal Disorders Drugs Market Competitive Landscape

    20.1. Competitive Market Overview

    20.2. Market Shares

    20.3. Company Profiles

    20.3.1. Sanofi S.A

    20.3.1.1. Company Overview

    20.3.1.2. Products And Services

    20.3.1.3. Strategy

    20.3.1.4. Financial Performance

    20.3.2. Pfizer Inc

    20.3.2.1. Company Overview

    20.3.2.2. Products And Services

    20.3.2.3. Strategy

    20.3.2.4. Financial Performance

    20.3.3. Bristol-Myers Squibb

    20.3.3.1. Company Overview

    20.3.3.2. Products And Services

    20.3.3.3. Strategy

    20.3.3.4. Financial Performance

    20.3.4. Eli Lilly And Company

    20.3.4.1. Company Overview

    20.3.4.2. Products And Services

    20.3.4.3. Strategy

    20.3.4.4. Financial Performance

    20.3.5. Mitsubishi Tanabe Pharma Corporation

    20.3.5.1. Company Overview

    20.3.5.2. Products And Services

    20.3.5.3. Strategy

    20.3.5.4. Financial Performance

    21. Key Mergers And Acquisitions In The Musculoskeletal Disorders Drugs Market

    22. Market Background: Pharmaceutical Drugs Market

    22.1. Pharmaceutical Drugs Market Characteristics

    22.2. Pharmaceutical Drugs Market Historic and Forecast, 2016-2021, 2021-2026F, 2031F Growth, By Segment, Value ($ Billion), Global

    22.3. Global Pharmaceutical Drugs Market, 2021, By Region, Value ($ Billion)

    22.4. Global Pharmaceutical Drugs Market, 2016-2021, 2021-2026F, 2031F, Historic And Forecast, By Region

    22.5. Global Pharmaceutical Drugs Market, 2016-2021, 2021-2026F, 2031F, Segmentation By Type, Value ($ Billion)

    23. Recommendations

    23.1. Global Musculoskeletal Disorders Drugs Market In 2026- Growth Countries

    23.2. Global Musculoskeletal Disorders Drugs Market In 2026- Growth Segments

    23.3. Global Musculoskeletal Disorders Drugs Market In 2026- Growth Strategies

    24. Appendix

    24.1. NAICS Definitions Of Industry Covered In This Report

    24.2. Abbreviations

    24.3. Currencies

    24.4. Research Inquiries

    24.5. The Business Research Company

    25. Copyright And Disclaimer

List Of Tables

    Table 1: Historic Market Growth, Value ($ Billion)
  • Table 2: Forecast Market Growth, Value ($ Billion)
  • Table 3: Global Musculoskeletal Disorders Drugs Market, 2021, By Region, Value ($ Billion)
  • Table 4: Global Musculoskeletal Disorders Drugs Market, 2016-2021, 2021-2026F, 2031F, Historic And Forecast, By Region
  • Table 5: Global Musculoskeletal Disorders Drugs Market, Growth And Market Share Comparison, By Region
  • Table 6: Global Musculoskeletal Disorders Drugs Market, Segmentation By Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 7: Global Musculoskeletal Disorders Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 8: Global Musculoskeletal Disorders Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 9: Global Musculoskeletal Disorders Drugs Market, Segmentation By Drug Classification, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 10: Global Musculoskeletal Disorders Drugs Market, Segmentation By Mode Of Purchase, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 11: Musculoskeletal Disorders Drugs Market Size, Percentage Of GDP, 2016-2026, Global
  • Table 12: Per Capita Average Musculoskeletal Disorders Drugs Market Expenditure, 2016-2026, Global
  • Table 13: Asia-Pacific, Musculoskeletal Disorders Drugs Market, 2021, By Country, Value ($ Billion)
  • Table 14: Asia-Pacific, Musculoskeletal Disorders Drugs Market, 2016-2021, 2021-2026F, 2031F, Historic And Forecast, By Country
  • Table 15: Asia-Pacific, Musculoskeletal Disorders Drugs Market, 2016-2021, 2021-2026F, 2031F, Growth And Market Share Comparison, By Country
  • Table 16: Per Capita Average Musculoskeletal Disorders Drugs Expenditure, 2016-2026, Asia-Pacific Countries
  • Table 17: Rheumatoid Arthritis Prevalence Rate, Musculoskeletal Disorders Drugs Market, Musculoskeletal Disorders Drugs Market/Rheumatoid Arthritis Prevalence Rate, 2021, Asia-Pacific Countries
  • Table 18: Asia-Pacific Musculoskeletal Disorders Drugs Market, Segmentation By Type, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Table 19: China Musculoskeletal Disorders Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Table 20: China Musculoskeletal Disorders Drugs Market, Segmentation By Type, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Table 21: Australia Musculoskeletal Disorders Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Table 22: Australia Musculoskeletal Disorders Drugs Market, Segmentation By Type, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Table 23: Hong Kong Musculoskeletal Disorders Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Table 24: India Musculoskeletal Disorders Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Table 25: India Musculoskeletal Disorders Drugs Market, Segmentation By Type, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Table 26: Indonesia Musculoskeletal Disorders Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Table 27: Indonesia Musculoskeletal Disorders Drugs Market, Segmentation By Type, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Table 28: Japan Musculoskeletal Disorders Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Table 29: Japan Musculoskeletal Disorders Drugs Market, Segmentation By Type, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Table 30: Malaysia Musculoskeletal Disorders Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Table 31: New Zealand Musculoskeletal Disorders Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Table 32: Philippines Musculoskeletal Disorders Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Table 33: Singapore Musculoskeletal Disorders Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Table 34: South Korea Musculoskeletal Disorders Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Table 35: Thailand Musculoskeletal Disorders Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Table 36: Vietnam Musculoskeletal Disorders Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Table 37: Western Europe, Musculoskeletal Disorders Drugs Market, 2021, By Country, Value ($ Billion)
  • Table 38: Western Europe, Musculoskeletal Disorders Drugs Market, 2016-2021, 2021-2026F, 2031F, Historic And Forecast, By Country
  • Table 39: Western Europe, Musculoskeletal Disorders Drugs Market, 2016-2021, 2021-2026F, 2031F, Growth And Market Share Comparison, By Country
  • Table 40: Per Capita Average Musculoskeletal Disorders Drugs Expenditure, 2016-2026, Western Europe Countries
  • Table 41: Rheumatoid Arthritis Prevalence Rate, Musculoskeletal Disorders Drugs Market, Musculoskeletal Disorders Drugs Market/Rheumatoid Arthritis Prevalence Rate, 2021, Western Europe Countries
  • Table 42: Western Europe Musculoskeletal Disorders Drugs Market, Segmentation By Type, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Table 43: Austria Musculoskeletal Disorders Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Table 44: Belgium Musculoskeletal Disorders Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Table 45: Denmark Musculoskeletal Disorders Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Table 46: Finland Musculoskeletal Disorders Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Table 47: France Musculoskeletal Disorders Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Table 48: France Musculoskeletal Disorders Drugs Market, Segmentation By Type, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Table 49: Germany Musculoskeletal Disorders Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Table 50: Germany Musculoskeletal Disorders Drugs Market, Segmentation By Type, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Table 51: Ireland Musculoskeletal Disorders Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Table 52: Italy Musculoskeletal Disorders Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Table 53: Netherlands Musculoskeletal Disorders Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Table 54: Norway Musculoskeletal Disorders Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Table 55: Portugal Musculoskeletal Disorders Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Table 56: Spain Musculoskeletal Disorders Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Table 57: Sweden Musculoskeletal Disorders Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Table 58: Switzerland Musculoskeletal Disorders Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Table 59: UK Musculoskeletal Disorders Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Table 60: UK Musculoskeletal Disorders Drugs Market, Segmentation By Type, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Table 61: Eastern Europe, Musculoskeletal Disorders Drugs Market, 2021, By Country, Value ($ Billion)
  • Table 62: Eastern Europe, Musculoskeletal Disorders Drugs Market, 2016-2021, 2021-2026F, 2031F, Historic And Forecast, By Country
  • Table 63: Eastern Europe, Musculoskeletal Disorders Drugs Market, 2016-2021, 2021-2026F, 2031F, Growth And Market Share Comparison, By Country
  • Table 64: Per Capita Average Musculoskeletal Disorders Drugs Expenditure, 2016-2026, Eastern Europe Countries
  • Table 65: Rheumatoid Arthritis Prevalence Rate, Musculoskeletal Disorders Drugs Market, Musculoskeletal Disorders Drugs Market/Rheumatoid Arthritis Prevalence Rate, 2021, Eastern Europe Countries
  • Table 66: Eastern Europe Musculoskeletal Disorders Drugs Market, Segmentation By Type, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Table 67: Czech Republic Musculoskeletal Disorders Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Table 68: Poland Musculoskeletal Disorders Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Table 69: Romania Musculoskeletal Disorders Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Table 70: Russia Musculoskeletal Disorders Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Table 71: Russia Musculoskeletal Disorders Drugs Market, Segmentation By Type, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Table 72: North America, Musculoskeletal Disorders Drugs Market, 2021, By Country, Value ($ Billion)
  • Table 73: North America, Musculoskeletal Disorders Drugs Market, 2016-2021, 2021-2026F, 2031F, Historic And Forecast, By Country
  • Table 74: North America, Musculoskeletal Disorders Drugs Market, 2016-2021, 2021-2026F, 2031F, Growth And Market Share Comparison, By Country
  • Table 75: Per Capita Average Musculoskeletal Disorders Drugs Expenditure, 2016-2026, North America Countries
  • Table 76: Rheumatoid Arthritis Prevalence Rate, Musculoskeletal Disorders Drugs Market, Musculoskeletal Disorders Drugs Market/Rheumatoid Arthritis Prevalence Rate, 2021, North America Countries
  • Table 77: North America Musculoskeletal Disorders Drugs Market, Segmentation By Type, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Table 78: Canada Musculoskeletal Disorders Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Table 79: Mexico Musculoskeletal Disorders Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Table 80: USA Musculoskeletal Disorders Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Table 81: USA Musculoskeletal Disorders Drugs Market, Segmentation By Type, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Table 82: South America, Musculoskeletal Disorders Drugs Market, 2021, By Country, Value ($ Billion)
  • Table 83: South America, Musculoskeletal Disorders Drugs Market, 2016-2021, 2021-2026F, 2031F, Historic And Forecast, By Country
  • Table 84: South America, Musculoskeletal Disorders Drugs Market, 2016-2021, 2021-2026F, 2031F, Growth And Market Share Comparison, By Country
  • Table 85: Per Capita Average Musculoskeletal Disorders Drugs Expenditure, 2016-2026, South America Countries
  • Table 86: Rheumatoid Arthritis Prevalence Rate, Musculoskeletal Disorders Drugs Market, Musculoskeletal Disorders Drugs Market/Rheumatoid Arthritis Prevalence Rate, 2021, South America Countries
  • Table 87: South America Musculoskeletal Disorders Drugs Market, Segmentation By Type, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Table 88: Argentina Musculoskeletal Disorders Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Table 89: Brazil Musculoskeletal Disorders Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Table 90: Brazil Musculoskeletal Disorders Drugs Market, Segmentation By Type, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Table 91: Chile Musculoskeletal Disorders Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Table 92: Colombia Musculoskeletal Disorders Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Table 93: Peru Musculoskeletal Disorders Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Table 94: Venezuela Musculoskeletal Disorders Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Table 95: Middle East, Musculoskeletal Disorders Drugs Market, 2021, By Country, Value ($ Billion)
  • Table 96: Middle East, Musculoskeletal Disorders Drugs Market, 2016-2021, 2021-2026F, 2031F, Historic And Forecast, By Country
  • Table 97: Middle East, Musculoskeletal Disorders Drugs Market, 2016-2021, 2021-2026F, 2031F, Growth And Market Share Comparison, By Country
  • Table 98: Per Capita Average Musculoskeletal Disorders Drugs Expenditure, 2016-2026, Middle East Countries
  • Table 99: Rheumatoid Arthritis Prevalence Rate, Musculoskeletal Disorders Drugs Market, Musculoskeletal Disorders Drugs Market/Rheumatoid Arthritis Prevalence Rate, 2021, Middle East Countries
  • Table 100: Middle East Musculoskeletal Disorders Drugs Market, Segmentation By Type, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Table 101: Saudi Arabia Musculoskeletal Disorders Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Table 102: Israel Musculoskeletal Disorders Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Table 103: Turkey Musculoskeletal Disorders Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Table 104: UAE Musculoskeletal Disorders Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Table 105: Africa, Musculoskeletal Disorders Drugs Market, 2021, By Country, Value ($ Billion)
  • Table 106: Africa, Musculoskeletal Disorders Drugs Market, 2016-2021, 2021-2026F, 2031F, Historic And Forecast, By Country
  • Table 107: Africa, Musculoskeletal Disorders Drugs Market, 2016-2021, 2021-2026F, 2031F, Growth And Market Share Comparison, By Country
  • Table 108: Per Capita Average Musculoskeletal Disorders Drugs Expenditure, 2016-2026, Africa Countries
  • Table 109: Rheumatoid Arthritis Prevalence Rate, Musculoskeletal Disorders Drugs Market, Musculoskeletal Disorders Drugs Market/Rheumatoid Arthritis Prevalence Rate, 2021, Africa Countries
  • Table 110: Africa Musculoskeletal Disorders Drugs Market, Segmentation By Type, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Table 111: Egypt Musculoskeletal Disorders Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Table 112: Nigeria Musculoskeletal Disorders Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Table 113: South Africa Musculoskeletal Disorders Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Table 114: Sanofi S.A Financial Performance
  • Table 115: Pfizer Inc Financial Performance
  • Table 116: Bristol-Myers Squibb Financial Performance
  • Table 117: Eli Lilly And Company Financial Performance
  • Table 118: Mitsubishi Tanabe Pharma Corporation Financial Performance
  • Table 119: Pharmaceutical Drugs Market Historic and Forecast, 2016-2021, 2021-2026F, 2031F, Growth, By Segment, Value ($ Billion), Global
  • Table 120: Global Pharmaceutical Drugs Market, 2021, By Region, Value ($ Billion)
  • Table 121: Global Pharmaceutical Drugs Market, 2016-2021, 2021-2026F, 2031F, Historic And Forecast, By Region
  • Table 122: Global Pharmaceutical Drugs Market, 2016-2021, 2021-2026F, 2031F, Segmentation By Type, Value ($ Billion)
  • Table 123: Global Musculoskeletal Disorders Drugs Market In 2026- Growth Countries
  • Table 124: Global Musculoskeletal Disorders Drugs Market In 2026- Growth Segments
  • Table 125: Global Musculoskeletal Disorders Drugs Market In 2026- Growth Strategies

List Of Figures

    Figure 1: Historic Market Growth, Value ($ Billion)
  • Figure 2: Forecast Market Growth, Value ($ Billion)
  • Figure 3: Global Musculoskeletal Disorders Drugs Market, 2021, By Region, Value ($ Billion)
  • Figure 4: Global Musculoskeletal Disorders Drugs Market, 2016-2021, 2021-2026F, 2031F, Historic And Forecast, By Region
  • Figure 5: Global Musculoskeletal Disorders Drugs Market, Growth And Market Share Comparison, By Region
  • Figure 6: Global Musculoskeletal Disorders Drugs Market, Segmentation By Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 7: Global Musculoskeletal Disorders Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 8: Global Musculoskeletal Disorders Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 9: Global Musculoskeletal Disorders Drugs Market, Segmentation By Drug Classification, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 10: Global Musculoskeletal Disorders Drugs Market, Segmentation By Mode Of Purchase, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 11: Musculoskeletal Disorders Drugs Market Size, Percentage Of GDP, 2016-2026, Global
  • Figure 12: Per Capita Average Musculoskeletal Disorders Drugs Market Expenditure, 2016-2026, Global
  • Figure 13: Asia-Pacific, Musculoskeletal Disorders Drugs Market, 2021, By Country, Value ($ Billion)
  • Figure 14: Asia-Pacific, Musculoskeletal Disorders Drugs Market, 2016-2021, 2021-2026F, 2031F, Historic And Forecast, By Country
  • Figure 15: Asia-Pacific, Musculoskeletal Disorders Drugs Market, 2016-2021, 2021-2026F, 2031F, Growth And Market Share Comparison, By Country
  • Figure 16: Per Capita Average Musculoskeletal Disorders Drugs Expenditure, 2016-2026, Asia-Pacific Countries
  • Figure 17: Rheumatoid Arthritis Prevalence Rate, Musculoskeletal Disorders Drugs Market, Musculoskeletal Disorders Drugs Market/Rheumatoid Arthritis Prevalence Rate, 2021, Asia-Pacific Countries
  • Figure 18: Asia-Pacific Musculoskeletal Disorders Drugs Market, Segmentation By Type, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Figure 19: China Musculoskeletal Disorders Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Figure 20: China Musculoskeletal Disorders Drugs Market, Segmentation By Type, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Figure 21: Australia Musculoskeletal Disorders Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Figure 22: Australia Musculoskeletal Disorders Drugs Market, Segmentation By Type, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Figure 23: Hong Kong Musculoskeletal Disorders Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Figure 24: India Musculoskeletal Disorders Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Figure 25: India Musculoskeletal Disorders Drugs Market, Segmentation By Type, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Figure 26: Indonesia Musculoskeletal Disorders Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Figure 27: Indonesia Musculoskeletal Disorders Drugs Market, Segmentation By Type, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Figure 28: Japan Musculoskeletal Disorders Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Figure 29: Japan Musculoskeletal Disorders Drugs Market, Segmentation By Type, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Figure 30: Malaysia Musculoskeletal Disorders Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Figure 31: New Zealand Musculoskeletal Disorders Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Figure 32: Philippines Musculoskeletal Disorders Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Figure 33: Singapore Musculoskeletal Disorders Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Figure 34: South Korea Musculoskeletal Disorders Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Figure 35: Thailand Musculoskeletal Disorders Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Figure 36: Vietnam Musculoskeletal Disorders Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Figure 37: Western Europe, Musculoskeletal Disorders Drugs Market, 2021, By Country, Value ($ Billion)
  • Figure 38: Western Europe, Musculoskeletal Disorders Drugs Market, 2016-2021, 2021-2026F, 2031F, Historic And Forecast, By Country
  • Figure 39: Western Europe, Musculoskeletal Disorders Drugs Market, 2016-2021, 2021-2026F, 2031F, Growth And Market Share Comparison, By Country
  • Figure 40: Per Capita Average Musculoskeletal Disorders Drugs Expenditure, 2016-2026, Western Europe Countries
  • Figure 41: Rheumatoid Arthritis Prevalence Rate, Musculoskeletal Disorders Drugs Market, Musculoskeletal Disorders Drugs Market/Rheumatoid Arthritis Prevalence Rate, 2021, Western Europe Countries
  • Figure 42: Western Europe Musculoskeletal Disorders Drugs Market, Segmentation By Type, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Figure 43: Austria Musculoskeletal Disorders Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Figure 44: Belgium Musculoskeletal Disorders Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Figure 45: Denmark Musculoskeletal Disorders Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Figure 46: Finland Musculoskeletal Disorders Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Figure 47: France Musculoskeletal Disorders Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Figure 48: France Musculoskeletal Disorders Drugs Market, Segmentation By Type, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Figure 49: Germany Musculoskeletal Disorders Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Figure 50: Germany Musculoskeletal Disorders Drugs Market, Segmentation By Type, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Figure 51: Ireland Musculoskeletal Disorders Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Figure 52: Italy Musculoskeletal Disorders Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Figure 53: Netherlands Musculoskeletal Disorders Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Figure 54: Norway Musculoskeletal Disorders Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Figure 55: Portugal Musculoskeletal Disorders Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Figure 56: Spain Musculoskeletal Disorders Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Figure 57: Sweden Musculoskeletal Disorders Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Figure 58: Switzerland Musculoskeletal Disorders Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Figure 59: UK Musculoskeletal Disorders Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Figure 60: UK Musculoskeletal Disorders Drugs Market, Segmentation By Type, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Figure 61: Eastern Europe, Musculoskeletal Disorders Drugs Market, 2021, By Country, Value ($ Billion)
  • Figure 62: Eastern Europe, Musculoskeletal Disorders Drugs Market, 2016-2021, 2021-2026F, 2031F, Historic And Forecast, By Country
  • Figure 63: Eastern Europe, Musculoskeletal Disorders Drugs Market, 2016-2021, 2021-2026F, 2031F, Growth And Market Share Comparison, By Country
  • Figure 64: Per Capita Average Musculoskeletal Disorders Drugs Expenditure, 2016-2026, Eastern Europe Countries
  • Figure 65: Rheumatoid Arthritis Prevalence Rate, Musculoskeletal Disorders Drugs Market, Musculoskeletal Disorders Drugs Market/Rheumatoid Arthritis Prevalence Rate, 2021, Eastern Europe Countries
  • Figure 66: Eastern Europe Musculoskeletal Disorders Drugs Market, Segmentation By Type, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Figure 67: Czech Republic Musculoskeletal Disorders Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Figure 68: Poland Musculoskeletal Disorders Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Figure 69: Romania Musculoskeletal Disorders Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Figure 70: Russia Musculoskeletal Disorders Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Figure 71: Russia Musculoskeletal Disorders Drugs Market, Segmentation By Type, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Figure 72: North America, Musculoskeletal Disorders Drugs Market, 2021, By Country, Value ($ Billion)
  • Figure 73: North America, Musculoskeletal Disorders Drugs Market, 2016-2021, 2021-2026F, 2031F, Historic And Forecast, By Country
  • Figure 74: North America, Musculoskeletal Disorders Drugs Market, 2016-2021, 2021-2026F, 2031F, Growth And Market Share Comparison, By Country
  • Figure 75: Per Capita Average Musculoskeletal Disorders Drugs Expenditure, 2016-2026, North America Countries
  • Figure 76: Rheumatoid Arthritis Prevalence Rate, Musculoskeletal Disorders Drugs Market, Musculoskeletal Disorders Drugs Market/Rheumatoid Arthritis Prevalence Rate, 2021, North America Countries
  • Figure 77: North America Musculoskeletal Disorders Drugs Market, Segmentation By Type, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Figure 78: Canada Musculoskeletal Disorders Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Figure 79: Mexico Musculoskeletal Disorders Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Figure 80: USA Musculoskeletal Disorders Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Figure 81: USA Musculoskeletal Disorders Drugs Market, Segmentation By Type, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Figure 82: South America, Musculoskeletal Disorders Drugs Market, 2021, By Country, Value ($ Billion)
  • Figure 83: South America, Musculoskeletal Disorders Drugs Market, 2016-2021, 2021-2026F, 2031F, Historic And Forecast, By Country
  • Figure 84: South America, Musculoskeletal Disorders Drugs Market, 2016-2021, 2021-2026F, 2031F, Growth And Market Share Comparison, By Country
  • Figure 85: Per Capita Average Musculoskeletal Disorders Drugs Expenditure, 2016-2026, South America Countries
  • Figure 86: Rheumatoid Arthritis Prevalence Rate, Musculoskeletal Disorders Drugs Market, Musculoskeletal Disorders Drugs Market/Rheumatoid Arthritis Prevalence Rate, 2021, South America Countries
  • Figure 87: South America Musculoskeletal Disorders Drugs Market, Segmentation By Type, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Figure 88: Argentina Musculoskeletal Disorders Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Figure 89: Brazil Musculoskeletal Disorders Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Figure 90: Brazil Musculoskeletal Disorders Drugs Market, Segmentation By Type, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Figure 91: Chile Musculoskeletal Disorders Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Figure 92: Colombia Musculoskeletal Disorders Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Figure 93: Peru Musculoskeletal Disorders Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Figure 94: Venezuela Musculoskeletal Disorders Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Figure 95: Middle East, Musculoskeletal Disorders Drugs Market, 2021, By Country, Value ($ Billion)
  • Figure 96: Middle East, Musculoskeletal Disorders Drugs Market, 2016-2021, 2021-2026F, 2031F, Historic And Forecast, By Country
  • Figure 97: Middle East, Musculoskeletal Disorders Drugs Market, 2016-2021, 2021-2026F, 2031F, Growth And Market Share Comparison, By Country
  • Figure 98: Per Capita Average Musculoskeletal Disorders Drugs Expenditure, 2016-2026, Middle East Countries
  • Figure 99: Rheumatoid Arthritis Prevalence Rate, Musculoskeletal Disorders Drugs Market, Musculoskeletal Disorders Drugs Market/Rheumatoid Arthritis Prevalence Rate, 2021, Middle East Countries
  • Figure 100: Middle East Musculoskeletal Disorders Drugs Market, Segmentation By Type, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Figure 101: Saudi Arabia Musculoskeletal Disorders Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Figure 102: Israel Musculoskeletal Disorders Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Figure 103: Turkey Musculoskeletal Disorders Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Figure 104: UAE Musculoskeletal Disorders Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Figure 105: Africa, Musculoskeletal Disorders Drugs Market, 2021, By Country, Value ($ Billion)
  • Figure 106: Africa, Musculoskeletal Disorders Drugs Market, 2016-2021, 2021-2026F, 2031F, Historic And Forecast, By Country
  • Figure 107: Africa, Musculoskeletal Disorders Drugs Market, 2016-2021, 2021-2026F, 2031F, Growth And Market Share Comparison, By Country
  • Figure 108: Per Capita Average Musculoskeletal Disorders Drugs Expenditure, 2016-2026, Africa Countries
  • Figure 109: Rheumatoid Arthritis Prevalence Rate, Musculoskeletal Disorders Drugs Market, Musculoskeletal Disorders Drugs Market/Rheumatoid Arthritis Prevalence Rate, 2021, Africa Countries
  • Figure 110: Africa Musculoskeletal Disorders Drugs Market, Segmentation By Type, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Figure 111: Egypt Musculoskeletal Disorders Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Figure 112: Nigeria Musculoskeletal Disorders Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Figure 113: South Africa Musculoskeletal Disorders Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Figure 114: Sanofi S.A Financial Performance
  • Figure 115: Pfizer Inc Financial Performance
  • Figure 116: Bristol-Myers Squibb Financial Performance
  • Figure 117: Eli Lilly And Company Financial Performance
  • Figure 118: Mitsubishi Tanabe Pharma Corporation Financial Performance
  • Figure 119: Pharmaceutical Drugs Market Historic and Forecast, 2016-2021, 2021-2026F, 2031F, Growth, By Segment, Value ($ Billion), Global
  • Figure 120: Global Pharmaceutical Drugs Market, 2021, By Region, Value ($ Billion)
  • Figure 121: Global Pharmaceutical Drugs Market, 2016-2021, 2021-2026F, 2031F, Historic And Forecast, By Region
  • Figure 122: Global Pharmaceutical Drugs Market, 2016-2021, 2021-2026F, 2031F, Segmentation By Type, Value ($ Billion)
  • Figure 123: Global Musculoskeletal Disorders Drugs Market In 2026- Growth Countries
  • Figure 124: Global Musculoskeletal Disorders Drugs Market In 2026- Growth Segments
  • Figure 125: Global Musculoskeletal Disorders Drugs Market In 2026- Growth Strategies
View Report
View Report
View Report
View Report
View Report
View Report
View Report
View Report

Frequently Asked Questions

What is the definition of the musculoskeletal disorders drugs market?

The musculoskeletal disorders drugs market consists of sales of musculoskeletal disorders drugs and related services by entities that produce musculoskeletal disorders drugs to treat musculoskeletal disorders such as arthritis, osteoporosis, osteomalacia, and other disorders. request a sample here

How will the musculoskeletal disorders drugs market drivers and restraints affect musculoskeletal disorders drugs market dynamics? What forces will shape the musculoskeletal disorders drugs industry going forward?

The musculoskeletal disorders drugs market growth is aided by aging population profile of most countries. However, some musculoskeletal disorders drugs market restraints include regulatory changes leading to increased costs relating to new product development and service offerings to clients. request a sample here

What is the forecast market size of the musculoskeletal disorders drugs market?

The musculoskeletal disorders drugs market forecast is expected to reach $100.76 billion in 2025 at a compound annual growth rate of 4%. request a sample here

How is the musculoskeletal disorders drugs market segmented?

The global musculoskeletal disorders drugs market is segmented -
1) By Type: Drugs For Rheumatoid Arthritis, Muscle Relaxants, Other Musculoskeletal Disorders Drugs
2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies/ Drug Stores, Others
3) By Route Of Administration: Oral, Parenteral, Others
4) By Drug Classification: Branded Drugs, Generic Drugs
5) By Mode Of Purchase: Prescription-Based Drugs, Over-The-Counter Drugs
request a sample here

Which region has largest share, and what is the market size and growth by geography according to the musculoskeletal disorders drugs global market report?

For more detail on this, request a sample here.

Who are the key players of the global musculoskeletal disorders drugs market?

Top competitors in the musculoskeletal disorders drugs market are F. Hoffmann-La Roche Ltd, GlaxosmithKline Plc, Pfizer Inc, Abbott Laboratories Inc, Daiichi Sankyo Company. request a sample here.

What are the key trends in the global musculoskeletal disorders drugs market?

Major trends influencing the musculoskeletal disorders drugs market include rise in combination therapy request a sample here.

What are the major opportunities in the musculoskeletal disorders drugs market and the approaches companies can take to take advantage of them?

For detail on the future and current opportunities in the global musculoskeletal disorders drugs market, request a sample here.

How does the musculoskeletal disorders drugs market relate to the overall economy and other similar markets?